Akeso

This study is testing new drug combinations for people with advanced colorectal cancer that has not responded to standard treatments. It involves about 170 participants and tests different approaches, including using two experimental drugs together, with or without standard chemo…

This large, late-stage study is testing whether adding a new immunotherapy drug called AK104 to standard chemotherapy helps women with advanced cervical cancer that has returned or spread. The goal is to see if this combination can better control the cancer, helping patients live…

This study is testing whether a new drug called AK112, which targets two cancer pathways at once, works better when combined with standard chemotherapy for advanced non-small cell lung cancer (NSCLC). It involved 265 adults with stage IIIB/C or IV NSCLC to see if the combination …

This study is testing a combination of two investigational drugs, AK127 and AK112, in adults with advanced solid tumors that have progressed after standard treatments. The main goals are to find a safe dose and see if the combination can shrink tumors or slow their growth. It is …

This study is testing whether adding two new drugs, AK117 and AK112, to standard chemotherapy works better for people with advanced triple-negative breast cancer that has spread. It will involve about 120 patients who have not yet received treatment for their advanced cancer. The…

This large Phase 3 trial compares a new drug called AK112 against the established treatment pembrolizumab for people with advanced non-small cell lung cancer. It aims to see if AK112 can better control the cancer and help patients live longer without their disease getting worse. …

This study is testing two experimental drugs, AK112 and AK117, either alone or together, for people with metastatic colorectal cancer that has spread and cannot be surgically removed. The main goals are to see if these drugs can shrink tumors, control the cancer's growth, and are…

This large Phase 3 study compares two different immunotherapy combinations for people with advanced bile duct cancer that cannot be removed by surgery. Researchers are testing whether a new drug called AK112 works better than the established drug durvalumab when both are given wi…

This study is testing the safety and effectiveness of two immunotherapy drugs, AK112 and AK104, given with or without standard chemotherapy, for people with advanced non-small cell lung cancer. It aims to see if this combination can better control the cancer and help patients liv…

This study is testing a new drug called AK112, which targets two cancer pathways at once. It is given to patients before and after surgery for operable non-small cell lung cancer, either alone or combined with standard chemotherapy. The goal is to see if this approach helps shrin…

This study is for people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) where standard targeted pills have stopped working. It compares a new drug, AK112, combined with two common chemotherapy drugs against the same chemotherapy with a placebo. The …

This study is testing a combination of two new drugs, AK112 and AK117, for people with advanced cancers that have spread or returned. The main goals are to see if the treatment is safe and if it can shrink or control tumors. It is open to adults with certain types of head and nec…

This study is testing the safety and effectiveness of two new immunotherapy drugs (AK112 and Cadonilimab) when given with standard chemotherapy as the first treatment for metastatic pancreatic cancer. It involves 110 adults with advanced pancreatic cancer who have not yet receive…

This study aims to see if a cancer drug called AK112, made at a new factory, behaves the same way in the body as the drug made at the original, approved factory. It will involve 108 healthy male volunteers to compare how long the drug stays in their blood and check for safety. Th…